consumer genomics

In an effort to lift patient access barriers, the company is launching a model whereby consumers will be able to initiate test orders online.

Blockchain-based startup EncrypGen will take advantage of Murrieta Genomics' sequencing lab and business services to market its Gene-Chain platform for data sharing.

As consumer genomics firms ramp up marketing for Alzheimer's risk tests, one  support group says experts should help people understand the results and potential negative effects.

Myriad CEO Mark Capone said earnings during the quarter exceeded expectations based on strong volume growth from hereditary cancer and new products.

The genetic testing community is having a tough time deciphering FDA's intentions based on its authorization of 23andMe’s PGx test and a recent safety alert.

Few Eyebrows Up

Time reports that some experts have raised concerns about 23andMe's new direct-to-consumer pharmacogenetic tests.

The market authorization came with a number of caveats and special requirements that 23andMe must follow when selling its PGx tests to consumers.

The project is informing participants of familial hypercholesterolemia genetic test results, and hereditary breast and ovarian cancer, and Lynch syndrome results will follow.

ADx Healthcare is selling an APOE test on the Helix marketplace, while HealthLytix and Dash Genomics are marketing a polygenic hazard score for late-onset Alzheimer's.

23andMe is evaluating how third-party services are impacting customers' experiences and would like to see those services be more complementary to its own efforts.

Pages

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.